Uterine and Adnexa Procedures for Ovarian DRG 737

Perioperative multimodal therapy trials examining combinations of surgical cytoreduction with perioperative systemic chemotherapy or targeted agents: these studies enroll patients undergoing uterine and adnexa procedures for suspected ovarian or adnexal malignancy with comorbid complications (the CC component), and test timing or sequencing of systemic therapy (neoadjuvant vs immediate postoperative) and perioperative adjuncts to reduce tumor burden and complications. Research in this area addresses surgical morbidity and short-term recovery, helping providers optimize intraoperative decision-making and helping payers anticipate lengths of stay, ICU utilization, and bundled payment implications for high-acuity surgical admissions.
Comparative effectiveness studies of surgical approach and extent of resection in patients with ovarian or adnexal malignancy complicated by comorbid conditions: these observational or pragmatic randomized studies compare outcomes (perioperative complications, readmissions, need for reoperation) between minimally invasive, standard open laparotomy, and extended cytoreductive procedures specifically in patients with cardiorespiratory, metabolic, or other CC-level comorbidities. This research directly informs procedural choice for high-risk inpatients, supports guideline development for patient selection, and helps payers and hospitals evaluate resource use and expected complication-driven costs within this DRG.
Post-discharge outcomes and care coordination trials focusing on reducing readmissions and improving recovery after complex gynecologic oncology surgery: these interventional or cohort studies test discharge protocols, early outpatient surveillance, home-based supportive services, or enhanced recovery pathways tailored to patients with CC-level comorbidities following uterine and adnexa procedures. Results are relevant to providers aiming to lower postoperative complications and to payers interested in reducing 30-day readmissions, post-discharge costs, and variations in post-acute care utilization for this high-cost DRG.

Perioperative multimodal therapy trials examining combinations of surgical cytoreduction with perioperative systemic chemotherapy or targeted agents: these studies enroll patients undergoing uterine and adnexa procedures for suspected ovarian or adnexal malignancy with comorbid complications (the CC component), and test timing or sequencing of systemic therapy (neoadjuvant vs immediate postoperative) and perioperative adjuncts to reduce tumor burden and complications. Research in this area addresses surgical morbidity and short-term recovery, helping providers optimize intraoperative decision-making and helping payers anticipate lengths of stay, ICU utilization, and bundled payment implications for high-acuity surgical admissions.
Comparative effectiveness studies of surgical approach and extent of resection in patients with ovarian or adnexal malignancy complicated by comorbid conditions: these observational or pragmatic randomized studies compare outcomes (perioperative complications, readmissions, need for reoperation) between minimally invasive, standard open laparotomy, and extended cytoreductive procedures specifically in patients with cardiorespiratory, metabolic, or other CC-level comorbidities. This research directly informs procedural choice for high-risk inpatients, supports guideline development for patient selection, and helps payers and hospitals evaluate resource use and expected complication-driven costs within this DRG.
Post-discharge outcomes and care coordination trials focusing on reducing readmissions and improving recovery after complex gynecologic oncology surgery: these interventional or cohort studies test discharge protocols, early outpatient surveillance, home-based supportive services, or enhanced recovery pathways tailored to patients with CC-level comorbidities following uterine and adnexa procedures. Results are relevant to providers aiming to lower postoperative complications and to payers interested in reducing 30-day readmissions, post-discharge costs, and variations in post-acute care utilization for this high-cost DRG.

OpenPayer

Summary & Overview

Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy with CC: Inpatient Reimbursement Overview

DRG 737 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes